Cytokinetics jumps amid renewed takeover speculation
Cytokinetics (NASDAQ:CYTK) quickly rose 7.5% amid some renewed takeover speculation. There's some speculation that the company has had some fresh bid interest, according to traders, who cited a ...
Cytokinetics rumor highlighted in Betaville alert
A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...
Hosted on MSN16h
Morgan Stanley Upgrades Cytokinetics (CYTK)
Fintel reports that on February 13, 2025, Morgan Stanley upgraded their outlook for Cytokinetics (NasdaqGS:CYTK) from ...
Cytokinetics upgraded by Morgan Stanley on upside potential
Morgan Stanley has upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target. Read more ...
Cytokinetics upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...
Cytokinetics Names Robert E. Landry to Board of Directors
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...
Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...